Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,400
Employees6,400
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,400
Employees6,400

VRTX Key Statistics

Market cap
128.83B
Market cap128.83B
Price-Earnings ratio
29.00
Price-Earnings ratio29.00
Dividend yield
—
Dividend yield—
Average volume
1.18M
Average volume1.18M
High today
$517.68
High today$517.68
Low today
$505.52
Low today$505.52
Open price
$514.31
Open price$514.31
Volume
1.26M
Volume1.26M
52 Week high
$560.25
52 Week high$560.25
52 Week low
$403.16
52 Week low$403.16

Stock Snapshot

With a market cap of 128.83B, Vertex Pharmaceuticals(VRTX) trades at $508.28. The stock has a price-to-earnings ratio of 29.00.

On 2026-10-15, Vertex Pharmaceuticals(VRTX) stock traded between a low of $505.52 and a high of $517.68. Shares are currently priced at $508.28, which is +0.5% above the low and -1.8% below the high.

Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.26M, against a daily average of 1.18M.

During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $560.25 at its peak.

During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $403.16 at its lowest and $560.25 at its peak.

VRTX News

The Motley Fool 5h
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

In 2012, Vertex Pharmaceuticals (VRTX +2.86%) earned approval for the first medicine that targeted the underlying causes of cystic fibrosis (CF), a rare disease...

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Barchart 7h
What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release - Barchart.com

...

What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release - Barchart.com
Simply Wall St 13h
Does Early Pancreatic Recovery Change The Bull Case For Vertex Pharmaceuticals?

Vertex Pharmaceuticals reported interim data from an open label extension study of ALYFTREK in 2 to 5 year old children with cystic fibrosis, showing recovery o...

Does Early Pancreatic Recovery Change The Bull Case For Vertex Pharmaceuticals?

Analyst ratings

77%

of 35 ratings
Buy
77.1%
Hold
20%
Sell
2.9%

More VRTX News

The Motley Fool 2d
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Can the pioneer of mRNA vaccines outpace the king of cystic fibrosis treatments? Choosing between Moderna (MRNA -5.00%) and Vertex Pharmaceuticals (VRTX -0.60%)...

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 3d
Vertex Pharmaceuticals price target lowered to $667 from $672 at BofA

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $667 from $672 and keeps a Buy rating on the shares after updating estimates ahead of t...

Simply Wall St 4d
Vertex Pharmaceuticals Stock May Be 33% Undervalued Following New ALYFTREK Data

has delivered a powerful long term share price run, yet the key issue for anyone looking at the stock today is whether its current US$510.08 level is supported...

Vertex Pharmaceuticals Stock May Be 33% Undervalued Following New ALYFTREK Data
Zacks 6d
Vertex Pharmaceuticals Beats Stock Market Upswing: What Investors Need to Know

In the latest close session, Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) was up +1.36% at $510.08. The stock's change was more than the S&...

Vertex Pharmaceuticals Beats Stock Market Upswing: What Investors Need to Know
TipRanks 6d
Vertex and Moderna Advance CF mRNA Therapy: What VX-522 Trial Completion Means for Investors

Moderna (MRNA), Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study. The Phase 1/2 study titled “A Phase 1/2 Dose Escalation...

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.